Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-NODAGA-CG34
- Development stage
- Preclinical
- Lead developer
- University of Pittsburgh
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
64Cu-NODAGA-CG34 is a copper-64-labeled radiopharmaceutical PET imaging tracer developed by the University of Pittsburgh. It consists of CG34, a stabilized peptidomimetic fragment of the chemerin protein that acts as a high-affinity agonist of chemokine-like receptor 1 (CMKLR1, also known as ChemR23), conjugated to the chelator NODAGA via a 6-aminohexanoic acid linker. CMKLR1 is highly expressed on monocyte-derived macrophages and other innate immune cells involved in active inflammatory processes. By targeting CMKLR1, 64Cu-NODAGA-CG34 enables noninvasive positron emission tomography (PET) imaging of macrophage-driven inflammation. It has been investigated in preclinical models for monitoring acute lung injury (ALI), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and post-infarction myocardial inflammation and remodeling.
- Other names
- [64Cu]Cu-NODAGA-CG34[64Cu]NODAGA-CG34
02
Targets
CMKLR1 (Chemokine-like receptor 1)
Beyond the preview
Go deeper on 64Cu-NODAGA-CG34.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-NODAGA-CG34.